An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches the patent cliff for Keytruda.
An experimental antibody-drug conjugate from Merck and China-based Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Merck, Kelun score with sac-TMT in endometrial cancer trial
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi
Daiichi, AstraZeneca’s Enhertu breaks into early breast cancer with dual FDA approvals
Regeneron immunotherapy combo comes up short in melanoma trial
BeOne wins FDA approval in lymphoma race
Merck&Co. offre 32 miliardi di dollari per acquisire Revolution Medicines | MilanoFinanza News
Blockbuster Drug Gets Breast Cancer Approvals in Curative Setting
With new data, Regenxbio to seek FDA approval of Duchenne gene therapy
CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million
